Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

Seattle genetics Adcetris uses targeted antibodies in Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) with great success. Celldex licensed the technology from SGEN to create a targeted antibody for triple negative breast cancer that showed great promise, but the sample size was small.

I believe targeted antibodies have a big role to play in fighting cancer now and in the future. I have been invested in SGEN since 2006, ironically I sold some shares in 2009 to take up a position in Cellceutix. My thought at that time was this might be better then targeting antibodies.

OH
Again ironically, my ASCO play last year was Celldex but they botched the paperwork and missed the deadline to present at ASCO. The stock tanked so I am happy to see CTIX has their ASCO paperwork in order.